skip to main content
Idioma:
Primo Advanced Search
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search Query Term
Primo Advanced Search prefilters
Busca Simples
Refinado por: Nome da Publicação: Journal Of Clinical Oncology remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma
A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma

O'Day, S. ; Hodi, F. S. ; McDermott, D. F. ; Weber, R. W. ; Sosman, J. A. ; Haanen, J. B. ; Zhu, X. ; Yellin, M. J. ; Hoos, A. ; Urba, W. J.

Journal of clinical oncology, 2010-06, Vol.28 (18_suppl), p.4-4 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
2
Single-nucleotide polymorphisms (SNPs) in the endothelial nitric oxide synthase (NOS3) and vascular endothelial growth factor (VEGF) and its relationship to sunitinib-induced hypertension
Single-nucleotide polymorphisms (SNPs) in the endothelial nitric oxide synthase (NOS3) and vascular endothelial growth factor (VEGF) and its relationship to sunitinib-induced hypertension
Material Type:
Artigo 		Adicionar ao Meu Espaço

Single-nucleotide polymorphisms (SNPs) in the endothelial nitric oxide synthase (NOS3) and vascular endothelial growth factor (VEGF) and its relationship to sunitinib-induced hypertension

van der Veldt, A. A. ; Eechoute, K. ; Oosting, S. ; Kappers, M. H. ; Haanen, J. B. A. G. ; Reyners, A. K. L. ; Gelderblom, H. ; Guchelaar, H. ; Van Herpen, C. ; Boven, E. ; Mathijssen, R.

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.4611-4611 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
3
Re-induction with ipilimumab, gp100 peptide vaccine, or a combination of both from a phase III, randomized, double-blind, multicenter study of previously treated patients with unresectable stage III or IV melanoma
Re-induction with ipilimumab, gp100 peptide vaccine, or a combination of both from a phase III, randomized, double-blind, multicenter study of previously treated patients with unresectable stage III or IV melanoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

Re-induction with ipilimumab, gp100 peptide vaccine, or a combination of both from a phase III, randomized, double-blind, multicenter study of previously treated patients with unresectable stage III or IV melanoma

Hodi, F. S. ; O'Day, S. ; McDermott, D. F. ; Haanen, J. B. ; Robert, C. ; Zhu, X. ; Yellin, M. J. ; Ibrahim, R. A. ; Hoos, A. ; Wolchok, J. D.

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.8509-8509 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
4
The safety and efficacy of sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer
The safety and efficacy of sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

The safety and efficacy of sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer

Powles, T. ; Kayani, I. ; Blank, C. U. ; Chowdhury, S. ; Horenblas, S. ; Sarwar, N. ; Nathan, P. D. ; Boleti, E. ; Haanen, J. B. ; Bex, A.

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.4603-4603 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
5
Pharmacogenetic pathway analysis to identify factors for survival in metastatic renal cell cancer patients treated with sunitinib
Pharmacogenetic pathway analysis to identify factors for survival in metastatic renal cell cancer patients treated with sunitinib
Material Type:
Artigo 		Adicionar ao Meu Espaço

Pharmacogenetic pathway analysis to identify factors for survival in metastatic renal cell cancer patients treated with sunitinib

Eechoute, K. ; van der Veldt, A. A. ; Gelderblom, H. ; Gietema, J. A. ; Guchelaar, H. ; Van Erp, N. ; Boven, E. ; Haanen, J. B. ; Mathijssen, R. ; Wessels, J. A.

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.4521-4521 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
6
Choi response criteria for prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib
Choi response criteria for prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib
Material Type:
Artigo 		Adicionar ao Meu Espaço

Choi response criteria for prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib

van der Veldt, A. ; Meijerink, M. R. ; van den Eertwegh, A. J. ; Haanen, J. B. ; Boven, E.

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.5044-5044 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
7
Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600E BRAF-mutated melanoma
Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600E BRAF-mutated melanoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600E BRAF-mutated melanoma

Chapman, P. B. ; Hauschild, A. ; Robert, C. ; Larkin, J. M. G. ; Haanen, J. B. A. G. ; Ribas, A. ; Hogg, D. ; O'Day, S. ; Ascierto, P. A. ; Testori, A. ; Lorigan, P. ; Dummer, R. ; Sosman, J. A. ; Garbe, C. ; Lee, R. J. ; Nolop, K. B. ; Nelson, B. ; Hou, J. ; Flaherty, K. T. ; McArthur, G. A.

Journal of clinical oncology, 2011-06, Vol.29 (18_suppl), p.LBA4-LBA4 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
8
Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor RG7204 with dacarbazine in patients with V600E BRAF-mutated melanomas
Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor RG7204 with dacarbazine in patients with V600E BRAF-mutated melanomas
Material Type:
Artigo 		Adicionar ao Meu Espaço

Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor RG7204 with dacarbazine in patients with V600E BRAF-mutated melanomas

Chapman, P. B. ; Hauschild, A. ; Robert, C. ; Larkin, J. M. G. ; Haanen, J. B. A. G. ; Ribas, A. ; Hogg, D. ; O'Day, S. ; Ascierto, P. A. ; Testori, A. ; Lorigan, P. ; Dummer, R. ; Sosman, J. A. ; Garbe, C. ; Lee, R. J. ; Nolop, K. B. ; Nelson, B. ; Hou, J. ; Flaherty, K. T. ; McArthur, G. A.

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.LBA4-LBA4 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
9
Use of serum proteins identified by proteomics to predict prognosis in patients with metastatic renal cell cancer (mRCC) and comparison to the currently used MSKCC survival model
Use of serum proteins identified by proteomics to predict prognosis in patients with metastatic renal cell cancer (mRCC) and comparison to the currently used MSKCC survival model
Material Type:
Artigo 		Adicionar ao Meu Espaço

Use of serum proteins identified by proteomics to predict prognosis in patients with metastatic renal cell cancer (mRCC) and comparison to the currently used MSKCC survival model

Vermaat, J. ; van der Tweel, I. ; Mehra, N. ; Sleijfer, S. ; Engwegen, J. Y. ; Korse, C. M. ; Schellens, J. H. ; Haanen, J. B. ; Beijnen, J. H. ; Voest, E. E.

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.11078-11078 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
10
Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity
Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity
Material Type:
Artigo 		Adicionar ao Meu Espaço

Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity

van Erp, N. ; Mathijssen, R. H. ; van der Veldt, A. A. ; Haanen, J. B. ; Reyners, A. K. ; Eechoute, K. ; Boven, E. ; Wessels, J. A. ; Guchelaar, H. ; Gelderblom, H.

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.5006-5006 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Refinar Meus Resultados

Data de Publicação 

De até
Refinar

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.